Literature DB >> 27060073

Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.

Rahul Ravind1, Priyadarshini Venkatram Kumar1, Sasikala Prabaharan1.   

Abstract

Inflammatory breast cancer (IBC) is a relatively rare and aggressive subtype, accounting for nearly 2.5% of all diagnosed breast cancers worldwide. It is usually characterised by an acute onset, rapid clinical progression, poor prognosis and micrometastasis at the time of presentation. Prompt recognition of clinical symptoms and identification of warning signs are vital in diagnosing and appropriately treating a patient with IBC. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27060073      PMCID: PMC4840592          DOI: 10.1136/bcr-2016-214700

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

Review 1.  Inflammatory breast cancer.

Authors:  Wendy A Woodward; Massimo Cristofanilli
Journal:  Semin Radiat Oncol       Date:  2009-10       Impact factor: 5.934

2.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

3.  A novel human xenograft model of inflammatory breast cancer.

Authors:  M L Alpaugh; J S Tomlinson; Z M Shao; S H Barsky
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

Review 5.  Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings.

Authors:  Wei T Yang; Huong T Le-Petross; Homer Macapinlac; Selin Carkaci; Ana M Gonzalez-Angulo; Shaheenah Dawood; Erika Resetkova; Gabriel N Hortobagyi; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2007-07-26       Impact factor: 4.872

Review 6.  The epidemiology of inflammatory breast cancer.

Authors:  Paul H Levine; Carmela Veneroso
Journal:  Semin Oncol       Date:  2008-02       Impact factor: 4.929

7.  Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?

Authors:  P Bonnier; C Charpin; C Lejeune; S Romain; N Tubiana; B Beedassy; P M Martin; H Serment; L Piana
Journal:  Int J Cancer       Date:  1995-08-09       Impact factor: 7.396

8.  Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research.

Authors:  D Rea; A Francis; A M Hanby; V Speirs; E Rakha; A Shaaban; S Chan; S Vinnicombe; I O Ellis; S G Martin; L J Jones; F Berditchevski
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth?

Authors:  Michael Retsky; Romano Demicheli; William Hrushesky; Michael Baum; Isaac Gukas
Journal:  Cancers (Basel)       Date:  2010-03-30       Impact factor: 6.639

10.  Surgery as a double-edged sword: a clinically feasible approach to overcome the metastasis-promoting effects of surgery by blunting stress and prostaglandin responses.

Authors:  Marganit Benish; Shamgar Ben-Eliyahu
Journal:  Cancers (Basel)       Date:  2010-11-24       Impact factor: 6.639

View more
  1 in total

1.  Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer.

Authors:  Yuta Kawaguchi; Sayaka Kuba; Michi Morita; Xiangyue Meng; Hiroko Hayashi; Kazuma Kobayashi; Tomohiko Adachi; Masaaki Hidaka; Shinichiro Itoh; Kengo Kanetaka; Susumu Eguchi
Journal:  Intern Med       Date:  2022-01-13       Impact factor: 1.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.